Prevalence, Perception and Predictors of Concomitant Herbal Medicine Use among HIV/AIDS and Tuberculosis Patients in Metekel Zone, Northwest Ethiopia: A Cross-Sectional Study.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2022
2022
Historique:
received:
13
06
2022
revised:
31
10
2022
accepted:
03
11
2022
entrez:
28
11
2022
pubmed:
29
11
2022
medline:
29
11
2022
Statut:
epublish
Résumé
The use of herbal medicine is common in Ethiopia. However, evidence on the extent and predictors of concomitant use of herbal medicine with conventional treatment among HIV/AIDS and tuberculosis patients is limited. To assess the extent of concomitant use of herbal medicine with conventional therapy and associated factors among HIV/AIDS and tuberculosis patients in Metekel Zone, Northwest Ethiopia. A cross-sectional study was conducted from January to March 2020. HIV/AIDS and tuberculosis patients who visited the health facilities during the study were interviewed face-to-face using a structured and pretested questionnaire. The descriptive statistics and univariate and multivariate logistic regression analyses were conducted using SPSS version 25. A 412 patients on conventional treatment were included in this study; 355 (86.2%) were HIV patients, and 57 (13.8%) were TB patients. More than half, 217 (52.7%) participants reported using herbal medicine while on conventional therapy. Among those who claimed to have used herbal medicines, 32 (14.7%) received herbal medicine from traditional healers. About four of five herbal users did not disclose their use to their healthcare providers. The type of health facility on follow-up ( In the Metekel Zone, concomitant consumption of herbal medication is common among HIV/AIDS and tuberculosis patients. Furthermore, most patients did not disclose the healthcare practitioners about their herbal use. Therefore, healthcare practitioners must assess and counsel patients regarding the potential adverse effects and herb-drug interaction to optimize therapy.
Sections du résumé
Background
UNASSIGNED
The use of herbal medicine is common in Ethiopia. However, evidence on the extent and predictors of concomitant use of herbal medicine with conventional treatment among HIV/AIDS and tuberculosis patients is limited.
Objective
UNASSIGNED
To assess the extent of concomitant use of herbal medicine with conventional therapy and associated factors among HIV/AIDS and tuberculosis patients in Metekel Zone, Northwest Ethiopia.
Method
UNASSIGNED
A cross-sectional study was conducted from January to March 2020. HIV/AIDS and tuberculosis patients who visited the health facilities during the study were interviewed face-to-face using a structured and pretested questionnaire. The descriptive statistics and univariate and multivariate logistic regression analyses were conducted using SPSS version 25. A
Results
UNASSIGNED
412 patients on conventional treatment were included in this study; 355 (86.2%) were HIV patients, and 57 (13.8%) were TB patients. More than half, 217 (52.7%) participants reported using herbal medicine while on conventional therapy. Among those who claimed to have used herbal medicines, 32 (14.7%) received herbal medicine from traditional healers. About four of five herbal users did not disclose their use to their healthcare providers. The type of health facility on follow-up (
Conclusion
UNASSIGNED
In the Metekel Zone, concomitant consumption of herbal medication is common among HIV/AIDS and tuberculosis patients. Furthermore, most patients did not disclose the healthcare practitioners about their herbal use. Therefore, healthcare practitioners must assess and counsel patients regarding the potential adverse effects and herb-drug interaction to optimize therapy.
Identifiants
pubmed: 36437829
doi: 10.1155/2022/8235229
pmc: PMC9691294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8235229Informations de copyright
Copyright © 2022 Mamo Feyissa et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Afr J Tradit Complement Altern Med. 2016 Jul 03;13(4):123-131
pubmed: 28852728
Niger J Physiol Sci. 2013 Jun 30;28(1):109-12
pubmed: 23955417
Afr J Tradit Complement Altern Med. 2012 Jul 01;9(4):495-502
pubmed: 23983385
BMC Public Health. 2011 Nov 10;11:855
pubmed: 22074367
J Altern Complement Med. 2016 Nov;22(11):880-886
pubmed: 27631385
BMC Complement Altern Med. 2017 Aug 30;17(1):434
pubmed: 28854905
BMC Complement Altern Med. 2017 Aug 23;17(1):422
pubmed: 28830419
AIDS Care. 2012;24(11):1375-83
pubmed: 22292937
HIV AIDS (Auckl). 2020 Dec 15;12:941-949
pubmed: 33364851
Clin Microbiol Rev. 2011 Apr;24(2):351-76
pubmed: 21482729
BMC Public Health. 2008 Oct 21;8:365
pubmed: 18939987
Afr J Tradit Complement Altern Med. 2012 Jul 01;9(4):470-84
pubmed: 23983383
Complement Ther Med. 2017 Dec;35:14-19
pubmed: 29154059
Drug Metabol Drug Interact. 2011;26(2):53-63
pubmed: 21756221
PLoS One. 2018 Oct 3;13(10):e0203986
pubmed: 30281631
J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):11-13
pubmed: 27903949
Med Princ Pract. 2012;21(5):404-28
pubmed: 22236736
AIDS Care. 2008 Sep;20(8):1002-18
pubmed: 18608078
Am J Trop Med Hyg. 2005 Sep;73(3):571-5
pubmed: 16172483
Br J Clin Pharmacol. 2001 Nov;52(5):587-95
pubmed: 11736868
Am J Trop Med Hyg. 2007 Oct;77(4):757-63
pubmed: 17978084
Med Clin North Am. 2002 Jan;86(1):1-10
pubmed: 11795082
Syst Rev. 2019 Mar 5;8(1):68
pubmed: 30837002
Drugs. 2009;69(13):1777-98
pubmed: 19719333
Evid Based Complement Alternat Med. 2017;2017:1724581
pubmed: 28421118
Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003937
pubmed: 16034917
Front Pharmacol. 2014 Jan 10;4:177
pubmed: 24454289